<DOC>
	<DOCNO>NCT01569256</DOCNO>
	<brief_summary>Cabergoline prevents ovarian hyperstimulation syndrome high risk patient disrupt follicular fluid hormone microenvironmentally alter follicular fluid level insulin like growth hormone -I ( IGF-I ) , antimullerian hormone ( AMH ) , inhibin B hepatocyte growth factor ( HGF ) level woman PCOS high risk ovarian hyperstimulation syndrome ( OHSS ) .</brief_summary>
	<brief_title>Ovarian Hyperstimulation Syndrome Cabergoline</brief_title>
	<detailed_description>Dopamine agonist propose prophylactic treatment OHSS woman high risk OHSS , however possible mechanism action clearly know . In experimental study , inhibition vascular endothelial growth factor base pathway propose possible action mechanism dopamine agonist . However role hepatocyte growth factor ( HGF ) , insulin like growth factor-I ( IGF-I ) , inhibin B antimullerian hormone ( AMH ) cabergoline action OHSS prevention know .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<criteria>Development 14 lead follicle large 10 mm serum estradiol 3000 pg/ml end ovulation induction long luteal ovulation induction protocol . Having criterion PCOS Not inclusion criterion .</criteria>
	<gender>Female</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>